TLSI
TriSalus Life Sciences, Inc.Company Information
- Company Name
- TriSalus Life Sciences, Inc.
- CIK
- CIK0001826667
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- TLSI: Nasdaq, TLSIW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3841
- SIC Description
- Surgical & Medical Instruments & Apparatus
- Ticker
- TLSI
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-15
- Last sale
- 2026-05-15
- Shares purchased (TTM)
- 845,069
- Shares sold (TTM)
- 43,361
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 21,280,403
- Shares outstanding
- 58,296,711
- Ownership
- 36.50%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -0.82%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Derivative Financial Instruments Tranche Liability | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Assets | ||||||||||||||||||
| Derivative Financial Instruments Series B3 Warrant Liability | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Contingent Earnout Liability | - | - | - | - | - | - | - | - | - | - | - | 9 | ||||||
| Derivative Financial Instruments Warrant Liability | - | - | - | - | - | - | - | - | - | - | - | 5 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 46 | 57 | 20 | 23 | 26 | 13 | 9 | 11 | 16 | 4 | 12 | 21 | ||||||
| Accounts Receivable Net Current | 6 | 5 | 7 | 5 | 6 | 5 | 5 | 5 | 5 | 4 | 4 | 3 | ||||||
| Inventory Net | 4 | 4 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 2 | ||||||
| Prepaid Expense Current | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 3 | 2 | 3 | 3 | ||||||
| Assets Current | 60 | 68 | 32 | 33 | 38 | 25 | 21 | 24 | 28 | 13 | 21 | 29 | ||||||
| Property Plant And Equipment Net | - | - | - | - | - | - | - | 2 | 2 | 2 | - | 2 | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 2 | 2 | 2 | 2 | 2 | 2 | 2 | - | - | - | 2 | - | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Finite Lived Intangible Assets Net | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 62 | 71 | 35 | 36 | 41 | 29 | 24 | 27 | 32 | 18 | 25 | 34 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Trade Current | 4 | 4 | 3 | 4 | 2 | 3 | 2 | 1 | 2 | 2 | 3 | 2 | ||||||
| Accrued Liabilities Current | 7 | 7 | 8 | 7 | 7 | 8 | 7 | 8 | 9 | 11 | 11 | 7 | ||||||
| Other Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 11 | 12 | 11 | 11 | 9 | 12 | 10 | 10 | 12 | 14 | 15 | 9 | ||||||
| Long Term Debt Noncurrent | 33 | 33 | 33 | 33 | 32 | 32 | 22 | 22 | 21 | - | 0 | - | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 4 | 3 | 10 | 5 | 8 | 8 | 7 | 7 | 9 | 23 | 19 | - | ||||||
| Derivative Liabilities Noncurrent | 6 | 9 | 13 | 13 | 10 | 9 | 8 | 8 | 12 | 15 | 17 | - | ||||||
| Liabilities | 56 | 58 | 69 | 63 | 61 | 63 | 50 | 48 | 57 | 53 | 52 | 25 | ||||||
Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 345 | 342 | 297 | 294 | 279 | 256 | 254 | 249 | 242 | 227 | 222 | 221 | ||||||
| Retained Earnings Accumulated Deficit | -338 | -329 | -331 | -321 | -298 | -290 | -280 | -269 | -266 | -262 | -250 | -213 | ||||||
| Stockholders Equity | 7 | 13 | -34 | -27 | -19 | -34 | -26 | -20 | -25 | -36 | -27 | 8 | ||||||
| Liabilities And Stockholders Equity | 62 | 71 | 35 | 36 | 41 | 29 | 24 | 27 | 32 | 18 | 25 | 34 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | ||||||
| Preferred Stock Liquidation Preference | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | - | ||||||
| Common Stock Shares Issued | 61 | 61 | 50 | 50 | 38 | 32 | 31 | 30 | 27 | 27 | 26 | - | ||||||
| Shares Outstanding | 61 | 61 | 50 | 50 | 38 | 32 | 31 | 30 | 27 | 27 | 26 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTriSalus Life Sciences, Inc. (TLSI) — SEC Financial Statements & Analysis
TriSalus Life Sciences, Inc. (TLSI) is a surgical & medical instruments & apparatus company, incorporated in DE. TriSalus Life Sciences, Inc. trades on Nasdaq as: TLSI, TLSIW. TriSalus Life Sciences, Inc. (TLSI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, TriSalus Life Sciences, Inc. carries a market cap of $265.25M, a P/E ratio of -9.65x, a P/B ratio of 40.50x, a P/S ratio of 5.88x, an enterprise value of $252.03M, and an EV/EBITDA multiple of -8.42x. On profitability, it posts a gross margin of 85.79%, an operating margin of -67.68%, a net margin of -61.00%, a Return on Equity (ROE) of 427.22%, and a Return on Assets (ROA) of -53.00%. Per share, it reports EPS of $-0.47, diluted EPS of $-0.47, free cash flow per share of $-0.40, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 25.25% year-over-year, net income growth of -9.19% year-over-year, and EPS growth of -48.75% year-over-year. On the balance sheet, it maintains a current ratio of 5.35x, a quick ratio of 4.72x, working capital of $48.57M, a debt-to-equity ratio of 8.53x, a debt ratio of 0.9, an interest coverage ratio of -5.23x, free cash flow of $-23.28M (TTM), and net debt of $-13.22M. Figures sourced from SEC EDGAR.
- Market Cap
- $265.25M
- P/E TTM
- -9.65x
- EPS TTM
- $-0.47
- P/B TTM
- 40.50x
- ROE TTM
- 427.22%
- ROA TTM
- -53.00%
- Debt To Equity
- 8.53x
- Free Cash Flow TTM
- $-23.28M
- Net Revenue TTM Growth 1Y
- 25.25%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is TriSalus Life Sciences, Inc. in?
TriSalus Life Sciences, Inc. (TLSI) operates in the Surgical & Medical Instruments & Apparatus industry.
What exchange does TLSI trade on?
TriSalus Life Sciences, Inc. (TLSI) trades on the Nasdaq.
Where is TriSalus Life Sciences, Inc. incorporated?
TriSalus Life Sciences, Inc. is incorporated in DE.
When was TriSalus Life Sciences, Inc. (TLSI)'s most recent SEC filing?
TriSalus Life Sciences, Inc. (TLSI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is TLSI's market cap?
TriSalus Life Sciences, Inc. (TLSI) has a market capitalization of $265.25M as of 2026-06-30.
What is TLSI's EPS (earnings per share)?
TriSalus Life Sciences, Inc. (TLSI)'s trailing twelve month EPS is $-0.47 as of 2026-06-30.
What is TLSI's ROE (return on equity)?
TriSalus Life Sciences, Inc. (TLSI)'s trailing twelve month Return on Equity (ROE) is 427.22% as of 2026-06-30.
What is TLSI's ROA (return on assets)?
TriSalus Life Sciences, Inc. (TLSI)'s trailing twelve month Return on Assets (ROA) is -53.00% as of 2026-06-30.
What is TLSI's EV/EBITDA?
TriSalus Life Sciences, Inc. (TLSI)'s trailing twelve month EV/EBITDA is -8.42x as of 2026-06-30.